You are here

Article Text

Article menu

Download PDFPDF

Poster Presentation
Targeting the tumor vasculature with TEM8-specific T cells
  1. LaTerrica C Williams1,
  2. Sunitha Kakarla1,
  3. Simone Krebs2,
  4. Thuy Phung1,
  5. David Rowley1 and
  6. Stephen Gottschalk2
  1. Aff1 grid.39382.33000000012160926XBaylor College of Medicine Houston TX United States
  2. Aff2 grid.39382.33000000012160926XBaylor College of Medicine/Texas Childrens Hospital/Center for Cell and Gene Therapy Houston TX United States

http://dx.doi.org/10.1186/2051-1426-2-S3-P42

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Background

    T cell immunotherapy with genetically modified T cells expressing chimeric antigen receptors (CARs) has shown promise in preclinical models as well as early clinical studies. However, patients with solid tumors often do not respond as well as patients with hematological malignancies. This lack of efficacy for solid tumors is most likely due to several factors including a) emergence of immune escape mutants, and b) inability of tumor-specific T cells to recognize and destroy the vascular bed of solid tumors, which is critical for their malignant growth. The aim of this project is to generate CARs specific for tumor endothelial marker (TEM) 8, and evaluate their anti-vasculature and anti-tumor activity in preclinical tumor models.

    Methods/results

    We generated a retroviral encoding a TEM8-specific CAR consisting of the TEM8-specific single chain variable fragment AF344, a hinge/transmembrane domain, and a CD28.41BB.z endodomain. CD3/CD28-activated T cells were transduced with RD114-pseudotyped retroviral particles to generate TEM8-specific T cells and CAR expression was confirmed by FACS analysis. To evaluate the functionality of TEM8-specific T cells we used TEM8-negative cell lines (U373, A549, LM7, 293T) and 293T cells that were genetically modified to either express human TEM8 (293T.hTEM8) or murine TEM8 (293T.mTEM8). TEM8-specific T cells recognized target cells in an antigen-dependent fashion as judged by their ability to secrete pro-inflammatory cytokines (IFN-g and IL-2) in coculture assays, and kill TEM8-positive target cells. Importantly, TEM8-specific T cells readily recognized mTEM8-positive target cells, which will allow us to evaluate the safety and efficacy of TEM8-specific T cells in xenograft and immune competent murine tumor models.

    Conclusion

    We have constructed a TEM8-specific CAR and have shown that T cells expressing this CAR recognize and kill hTEM8- or mTEM8-positive target cells. Animal studies are in progress to determine their safety and efficacy. Targeting the tumor vasculature with TEM8-specific T cells may improve current T cell immunotherapies for solid tumors.